NEW YORK, July 28, 2014 /PRNewswire/ --
Today, Analysts Review released its research reports regarding Thermo Fisher Scientific Inc. (NYSE: TMO), Quest Diagnostics Inc (NYSE: DGX), Laboratory Corporation of America Holdings (NYSE: LH), PAREXEL International Corporation (NASDAQ: PRXL) and Quintiles Transnational Holdings Inc (NYSE: Q). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/5154-100free.
--
Thermo Fisher Scientific Inc. Research Reports
On July 23, 2014, Thermo Fisher Scientific Inc. (Thermo Fisher) reported its Q2 2014 financial results (period ended June 28, 2014). Revenue went up 33.4% YoY to $4.3 billion. Meanwhile, operating income registered $348.1 million compared with $375.4 million in Q2 2013. Net income stood at $278.5 million or $0.69 per diluted share versus $277.4 million or $0.76 per diluted share in Q2 2013. According to the Company, the decline in EPS resulted from the higher-acquisition related charges in 2014. Marc N. Casper, President and CEO of Thermo Fisher, said that the quarter's top line performance contributed to an outstanding growth in the Company's profits. "In the quarter, our teams executed very well, we made good progress on the Life Technologies integration - with synergies tracking ahead of plan - and we continued to invest in new technologies and capabilities to strengthen our global strategic position," Casper added. The Company updated its annual revenue and adjusted EPS guidance for full-year 2014, and expects revenues to be in the range between $16.86 billion and $16.98 billion. The full research reports on Thermo Fisher are available to download free of charge at:
http://www.analystsreview.com/Jul-28-2014/TMO/report.pdf
--
Quest Diagnostics Inc Research Reports
On July 23, 2014, Quest Diagnostics announced the election of Vicky Gregg as Director of the Board, effective immediately. The Company informed that Ms.Greg serves on the Boards of Team Health, First Horizon, TriZetto, and the Electric Power Board of Chattanooga. Further she previously held post as CEO of Blue Cross Blue Shield of Tennessee from 2003 to 2012. "During Vicky's tenure as CEO, Blue Cross Blue Shield of Tennessee substantially grew revenues, membership and market share," said Steve Rusckowski, President and CEO, Quest Diagnostics. "Her deep experience in healthcare from a payer's perspective will strengthen our Board and her insights will bolster our efforts to restore growth and drive operational excellence." The full research reports onQuest Diagnostics are available to download free of charge at:
http://www.analystsreview.com/Jul-28-2014/DGX/report.pdf
--
Laboratory Corporation of America Holdings Research Reports
On July 18, 2014, Laboratory Corporation of America Holdings (LabCorp) reported its Q2 2014 financial results. Net sales increased 3.3% YoY to $1.5 billion. However, net earnings stood at $141.3 million, or $1.64 per diluted share, compared with $151.9 million, or $1.62 per diluted share in Q2 2013. "We are pleased with the strong volume growth in the quarter and the sequential stability of revenue per requisition, which has been under pressure due to mix," said David P. King, Chairman and CEO of LabCorp. "We raised our 2014 Adjusted EPS guidance and continue to focus on executing our five-pillar strategy to grow our business and create shareholder value over the long term." The full research reports on LabCorp are available to download free of charge at:
http://www.analystsreview.com/Jul-28-2014/LH/report.pdf
--
PAREXEL International Corporation Research Reports
On July 10, 2014, PAREXEL International Corporation (PAREXEL International) announced that it will release its Q4 FY2014 and full-year FY 2014 financial results on August 6, 2014, after the close of the stock market. The Company informed that the earnings release will be followed by a conference call and live webcast on the next day, August 7, 2014 at 10:00 a.m. EDT. PAREXEL International added that the live webcast, as well as its replay, will be made available its Investor Relations website. The full research reports on PAREXEL International are available to download free of charge at:
http://www.analystsreview.com/Jul-28-2014/PRXL/report.pdf
--
Quintiles Transnational Holdings Inc Research Reports
On July 21, 2014, Quintiles Transnational Holdings Inc (Quintiles) reported that it received the 2014 "Britain's Healthiest Workplace" award, besting more than 80 companies for its commitment in employee health and wellness. The Company stated that Britain's Healthiest Company, the UK's largest survey into employee health, recognizes organizations that have an outstanding approach to their employees' health and wellbeing. Commenting on the recognition, Lindy Jones, Quintiles UK Head, said, "Our work on developing and commercializing medicines means that every day we are focused on improving the lives of people in the UK and beyond. A proactive approach to health and wellbeing is integral to living a full and healthy life, so we put a very strong emphasis on supporting employees in a number of areas such as physical activity and work life balance." The full research reports on Quintiles are available to download free of charge at:
http://www.analystsreview.com/Jul-28-2014/Q/report.pdf
--
About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.
===============
EDITOR'S NOTES:
===============
1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.analystsreview.com.
5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.analystsreview.com.
6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.analystsreview.com for consideration.
COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Analysts Review
